7th Annual Philadelphia-Japan Health Sciences Dialogue

In conjunction with the Licensing Executives Society (LES) and
Association of University Technology Managers (AUTM) Joint Spring Meeting

Therapies for Cancer

Tuesday, May 9, 2006 The Union League of Philadelphia

8:00 a.m. Registration and continental breakfast
8:15 a.m. – 5:00 p.m. Program (Lunch included)
5:00 p.m. – 6:30 p.m. Cocktail Networking Reception

Registration: $400 JASGP, NY Pharma Forum, JETRO NY Healthcare Study Group, PA BIO, LES, AUTM Members, Academia & Government; $500 Non-members

OVERVIEW
Cancer remains one of the most vexing health care problems facing the world, both in terms of therapy and cost. This is not for want of effort by institutions and businesses seeking solutions. There has been a proliferation of entities addressing the problem and a multitude of proposed solutions. Both Japan and the United States have been leaders in discovery and adoption of new therapeutic approaches. Progress had been slow, but there has been progress in fighting many forms of cancer. The amount of money being spent in cancer therapeutics research continues to grow. The 7th Annual Philadelphia-Japan Health Sciences Dialogue, featuring distinguished leaders in the field, is designed to take stock of what is happening in Japan and the United States in the fight against cancer, and to discern future trends in this important effort.

8:15-8:25 AM Welcome
Hiroshi Sato, Deputy Consul General and Deputy Chief of Mission, Consulate General of Japan in New York

8:30-8:50 Opening Remarks: Transformational Changes in Cancer Research and Treatment
Robert C. Young, M.D. President, Fox Chase Cancer Center

8:50-10:00 AM Distinctions and Similarities: Three Perspectives
Richard G. Pestell, M.D., Ph.D. Director, Kimmel Cancer Center, Thomas Jefferson University Hospital
Yasuhiro Fujiwara, M.D., Director, Outpatient Treatment Center, Japan National Cancer Center
Frank Pasqualone, Senior Vice President, Oncology, Bristol-Myers Squibb Co.

10:15-11:30 AM Evolving Trends in Cancer Therapy
Jeffrey M. Bockman, Ph.D., Vice President, Defined Health
David Jenkins, Director, Clinical Development, Cervarix TM, GlaxoSmithKline Biologicals
William U. Shipley, M.D., Massachusetts General Hospital Cancer Center

11:30-12:15 PM Product Pipeline: Targeted ≠ Narrow
Karen Bernstein, Chairman & Editor-in-Chief, BioCentury

12:15-1:45 PM Luncheon Address: Diagnostics & Biomarkers
Sean McDonald, President and CEO, Precision Therapeutics, Inc.
Moderator: Pradip K. Banerjee, Ph.D., President and CEO, Science Center

1:45-2:30 PM Unique Quality of Cancer Clinical Trials
Philip Sass, Ph.D., Executive Vice President & Chief Operating Officer, Morphotek Inc.
Linda Faux, Senior Director, Clinical Project Management, AstraZeneca Pharmaceuticals

2:30-3:30 PM Licenses and Business Development: Big Pharma
Ben Bonifant, Senior Practice Executive, Business Development Practice, Campbell Alliance
Nobuo Hanai, Ph.D., President and CEO, BioWa

3:45-4:45 PM Licenses and Business Development: The Biotechs
John Gill, President & CEO, TetraLogic Pharmaceutical Corporation
Ronald A. Pepin, Ph.D., Senior Vice President, Business Development, Medarex, Inc.
Masashi Suganuma, M.D., Ph.D., Vice President & COO, CanBas Co., Ltd.

4:45-5:00 PM Closing Remarks
Richard G. Pestell, M.D., Ph.D. Director, Kimmel Cancer Center, Thomas Jefferson University Hospital